Submission to the PBAC on the Base Case Discount Rate
Discount rates reflect how society values future outcomes compared to present outcomes. When applied to medicines, inappropriately high discount rates disadvantage treatments which have longer term health benefits, such as preventative or curative treatments, disproportionately discriminating against patients who could benefit from treatments where the benefits are realised over a longer period of time. As […]
Accelerating Access to Innovative Medicines
In 2022, Janssen commissioned Biointelect to explore current approaches to reimbursement for new and promising medicines in Australia and internationally. The resulting report, Accelerating Access to Innovative Medicines analyses Australia’s current reimbursement pathways and compares them with international policies designed to accelerate access to medicines. Research highlights that Australians are waiting longer for funded access […]
Regenerative Medicines Consortium Programme
Regenerative medicine (RM) promises to deliver ground-breaking therapies to Australian patients, with innovative approaches targeting a wide range of conditions including rare genetic diseases, cancers, chronic diseases, and organ damage. The global pipeline of clinical trials and investment in RM is booming, with 1,220 ongoing trials and US$19.9B raised in 2020, more than any previous […]
Cancer Survivorship in Australia
Over the past few decades, many cancers once thought to be fatal have become curable or amenable to long term control. BMS Australia commissioned Biointelect to conduct research into the Australian cancer survivorship landscape to see available programs and services for ‘cancer survivors’, their challenges, the gaps in services and how to address them. Biointelect […]
Immunisation Coalition – Enhancing adult vaccination coverage rates in Australia
This white paper examines the challenges and barriers to achieving higher rates of vaccination among Australian adults eligible for the National Immunisation Program (NIP), identifies priority areas for action and suggests evidence-based strategies to improve vaccine coverage rates.
Broadening the Evidence Report
Australia’s national health technology assessment (HTA) processes include the assessment of all prescription medicines where a listing on the Pharmaceutical Benefits Schedule (PBS) is sought. Listing on the PBS ensures subsidised, affordable and equitable access to medicines for Australian patients. It is especially important for high cost new medicines that may deliver significant improvements in […]
Roundtable: Response and resilience of the Australian life sciences sector
As the world emerges from the pandemic, it is critical to reflect on what has been learned and how to make strategic and sustainable investments for the future. Australia must identify and prioritise local investments, co-designed with stakeholders, and collaborating with the global life sciences sector. Effective investments have the potential to deliver benefits across […]
Fighting Super Bugs
In 2019, Biointelect and MTPConnect convened a multi-disciplinary workshop to bring together key stakeholders in the sector (Regulators, state / territory governments, academia, industry) to discuss the threat of antimicrobial resistance and what could be achieved in collaboration. This workshop led to the creation of the report ‘Fighting Superbugs: A Report on the Inaugural Meeting […]
White Paper on Precision Medicine in Australia
In 2019 MTPConnect commissioned Biointelect to facilitate a Round Table bringing together stakeholders in the sector to discuss the key issues surrounding technology, regulation and reimbursement, commercialisation, and implementation. This was done so MTPConnect can understand how to better support the sector in implementing precision medicine into the Australian healthcare system and contribute as a […]
Contemporary issues in valuing new oncology medicines: Do we need a new model?
In 2019 Biointelect hosted its second annual medicines policy symposium, this report summarises the main points of the presentation discussing this topic. The main discussions being the challenges of valuation of new oncology medicines, whether oncology submissions are optimal for assessment of value, what is to be learnt from the international discussion on valuation and […]
